
Winette T A Van Der Graaf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1220558/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2012, 379, 1879-1886.	6.3	1,752
2	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 415-423.	5.1	864
3	The impact of parental cancer on children and the family: a review of the literature. Cancer Treatment Reviews, 2004, 30, 683-694.	3.4	293
4	Mycobacterium ulcerans infection. Lancet, The, 1999, 354, 1013-1018.	6.3	271
5	Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2276-2282.	0.8	270
6	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. European Journal of Cancer, 2020, 127, 96-107.	1.3	243
7	Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins. Journal of Clinical Oncology, 2000, 18, 3211-3220.	0.8	222
8	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer, 2012, 118, 1649-1655.	2.0	222
9	Starting an Adolescent and Young Adult Program: Some Success Stories and Some Obstacles to Overcome. Journal of Clinical Oncology, 2010, 28, 4850-4857.	0.8	199
10	Monitoring and Predicting Response to Therapy with ¹⁸ F-FDG PET in Colorectal Cancer: A Systematic Review. Journal of Nuclear Medicine, 2009, 50, 43S-54S.	2.8	197
11	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience. Annals of Surgical Oncology, 2013, 20, 2937-2943.	0.7	190
12	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. Cancers, 2021, 13, 1.	1.7	189
13	Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocrine-Related Cancer, 2007, 14, 979-993.	1.6	187
14	Spinal Extradural Metastasis: Review of Current Treatment Options. Ca-A Cancer Journal for Clinicians, 2008, 58, 245-259.	157.7	185
15	Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer. Journal of Clinical Oncology, 2005, 23, 9130-9137.	0.8	182
16	Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study. Journal of Clinical Oncology, 2008, 26, 1239-1246.	0.8	181
17	Androgen Receptor–Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment Options. Journal of Clinical Oncology, 2011, 29, e473-e476.	0.8	164
18	An oncological view on the blood–testis barrier. Lancet Oncology, The, 2002, 3, 357-363.	5.1	158

#	Article	IF	CITATIONS
19	The insulin-like growth factor 1 receptor in cancer: Old focus, new future. European Journal of Cancer, 2007, 43, 1895-1904.	1.3	155
20	BREATH: Web-Based Self-Management for Psychological Adjustment After Primary Breast Cancer—Results of a Multicenter Randomized Controlled Trial. Journal of Clinical Oncology, 2015, 33, 2763-2771.	0.8	153
21	Time to Definitive Failure to the First Tyrosine Kinase inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and	0.8	148
22	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. Journal of Clinical Oncology, 2017, 35, 1713-1720.	0.8	148
23	Risk Factors for Buruli Ulcer Disease (Mycobacterium ulcerans Infection): Results from a Case-Control Study in Ghana. Clinical Infectious Diseases, 2005, 40, 1445-1453.	2.9	138
24	Histopathologic Features of <i>Mycobacterium ulcerans</i> Infection. Emerging Infectious Diseases, 2003, 9, 651-656.	2.0	134
25	Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics, 2005, 78, 433-438.	2.3	132
26	Beliefs and attitudes toward Buruli ulcer in Ghana American Journal of Tropical Medicine and Hygiene, 2002, 67, 207-213.	0.6	131
27	Emotional and behavioural functioning of children of a parent diagnosed with cancer: a cross-informant perspective. Psycho-Oncology, 2005, 14, 746-758.	1.0	127
28	The insulinâ€ i ke growth factor system and sarcomas. Journal of Pathology, 2009, 217, 469-482.	2.1	125
29	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. International Journal of Cancer, 2011, 129, 507-512.	2.3	120
30	Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nuclear Medicine Communications, 2004, 25, 433-438.	0.5	118
31	Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of CancerÁSoft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. European Journal of Cancer, 2016, 58, 62-72.	1.3	114
32	Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications. Journal of Clinical Oncology, 2012, 30, 308-315.	0.8	108
33	Solitary fibrous tumor – clinicopathologic, immunohistochemical and molecular analysis of 28 cases. Diagnostic Pathology, 2014, 9, 224.	0.9	107
34	The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World― Results from the Population-Based PROFILES Registry. Oncologist, 2020, 25, e722-e732.	1.9	107
35	Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. Lancet Oncology, The, 2017, 18, e166-e175.	5.1	100
36	Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncology, 2017, 13, 93-107.	1.1	99

#	Article	IF	CITATIONS
37	The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Research and Treatment, 2008, 110, 189-197.	1.1	97
38	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. Clinical Cancer Research, 2012, 18, 5780-5787.	3.2	96
39	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	2.0	96
40	Androgen deprivation therapy for androgen receptorâ€positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head and Neck, 2018, 40, 605-613.	0.9	94
41	Stress response symptoms in adolescent and young adult children of parents diagnosed with cancer. European Journal of Cancer, 2005, 41, 288-295.	1.3	92
42	First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget, 2016, 7, 80046-80058.	0.8	90
43	Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study. Journal of Clinical Oncology, 2005, 23, 8296-8304.	0.8	86
44	Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts. Molecular Cancer Therapeutics, 2010, 9, 1019-1027.	1.9	85
45	Age as an independent prognostic factor for survival of localised synovial sarcoma patients. British Journal of Cancer, 2015, 113, 1602-1606.	2.9	85
46	ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model. Journal of Nuclear Medicine, 2010, 51, 1565-1572.	2.8	84
47	Cancer in adolescents and young adults (15–29 years): A population-based study in the Netherlands 1989–2009. Acta OncolÁ³gica, 2012, 51, 922-933.	0.8	82
48	A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from <scp>T</scp> he <scp>N</scp> etherlands. International Journal of Cancer, 2018, 143, 758-766.	2.3	81
49	Quantitative assessment of P-glycoprotein function in the rat blood–brain barrier by distribution volume of [11C]verapamil measured with PET. NeuroImage, 2003, 20, 1775-1782.	2.1	80
50	Feasibility of Withholding Antibiotics in Selected Febrile Neutropenic Cancer Patients. Journal of Clinical Oncology, 2005, 23, 7437-7444.	0.8	79
51	Mycolactones and Mycobacterium ulcerans disease. Lancet, The, 2003, 362, 1062-1064.	6.3	78
52	Psychosocial Consequences for Children of a Parent With Cancer. Cancer Nursing, 2003, 26, 195-202.	0.7	77
53	PET–CT for radiotherapy treatment planning and response monitoring in solid tumors. Nature Reviews Clinical Oncology, 2011, 8, 233-242.	12.5	75
54	Post-Traumatic Growth and Resilience in Adolescent and Young Adult Cancer Patients: An Overview. Journal of Adolescent and Young Adult Oncology, 2018, 7, 1-14.	0.7	74

#	Article	IF	CITATIONS
55	Healthâ€related qualityâ€ofâ€life results from PALETTE: A randomized, doubleâ€blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer. 2015, 121, 2933-2941.	2.0	72
56	Mycobacterium ulcerans infection in Ashanti region, Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989, 83, 410-413.	0.7	71
57	Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts Journal of Clinical Oncology, 2018, 36, 92-92.	0.8	69
58	Systemic Treatment for Adults with Synovial Sarcoma. Current Treatment Options in Oncology, 2018, 19, 13.	1.3	67
59	Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncology, The, 2011, 12, 1053-1061.	5.1	66
60	Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. Journal of Nuclear Medicine, 2012, 53, 146-153.	2.8	66
61	Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview. Cancers, 2021, 13, 4847.	1.7	66
62	Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clinical Cancer Research, 2019, 25, 1479-1485.	3.2	63
63	Parental cancer. Cancer, 2006, 106, 1178-1187.	2.0	61
64	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. British Journal of Clinical Pharmacology, 2017, 83, 2195-2204.	1.1	61
65	Familyâ€oriented multilevel study on the psychological functioning of adolescent children having a mother with cancer. Psycho-Oncology, 2011, 20, 730-737.	1.0	60
66	Radiation-Induced Sarcoma: A Challenge for the Surgeon. Annals of Surgical Oncology, 2005, 12, 237-245.	0.7	59
67	In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemotherapy and Pharmacology, 2004, 54, 131-138.	1.1	58
68	Surgical management of rectal gastrointestinal stromal tumors. Journal of Surgical Oncology, 2013, 107, 320-323.	0.8	57
69	Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. European Urology, 2016, 69, 767-770.	0.9	57
70	Variability in axillary lymph node dissection for breast cancer. Journal of Surgical Oncology, 2004, 87, 4-12.	0.8	56
71	Imatinib, sunitinib and pazopanib: From flatâ€fixed dosing towards a pharmacokinetically guided personalized dose. British Journal of Clinical Pharmacology, 2020, 86, 258-273.	1.1	56
72	TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. Journal of Neuro-Oncology, 2006, 78, 161-171.	1.4	54

#	Article	IF	CITATIONS
73	The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncológica, 2009, 48, 927-931.	0.8	54
74	A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. European Journal of Cancer, 2020, 124, 77-87.	1.3	54
75	Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Research and Treatment, 2011, 129, 725-736.	1.1	53
76	Theranostic applications of antibodies in oncology. Molecular Oncology, 2014, 8, 799-812.	2.1	53
77	Serum HER2 levels are increased in patients with chronic heart failure. European Journal of Heart Failure, 2007, 9, 173-177.	2.9	51
78	Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. Acta Oncológica, 2017, 56, 288-294.	0.8	51
79	Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Tropical Medicine and International Health, 2005, 10, 1251-1257.	1.0	50
80	Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans. Hypertension, 2013, 61, 1060-1065.	1.3	50
81	Pretargeted ¹⁷⁷ Lu Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colonic Tumors in Mice. Journal of Nuclear Medicine, 2010, 51, 1780-1787.	2.8	49
82	Bevacizumab reduces tumor targeting of antiepidermal growth factor and antiâ€insulinâ€like growth factor 1 receptor antibodies. International Journal of Cancer, 2013, 133, 307-314.	2.3	49
83	Expression and clinical relevance of MET and ALK in Ewing sarcomas. International Journal of Cancer, 2013, 133, 427-436.	2.3	48
84	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head and Neck, 2017, 39, 140-146.	0.9	48
85	¹¹¹ In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib. Journal of Nuclear Medicine, 2010, 51, 1707-1715.	2.8	47
86	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. Clinical Sarcoma Research, 2014, 4, 7.	2.3	47
87	New positron emission tomography tracer [11 C]carvedilol reveals P-glycoprotein modulation kinetics. British Journal of Pharmacology, 2005, 145, 1045-1051.	2.7	46
88	The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. Oncotarget, 2014, 5, 12753-12768.	0.8	46
89	Next generation sequencing in synovial sarcoma reveals novel gene mutations. Oncotarget, 2015, 6, 34680-34690.	0.8	45
90	3′-Deoxy-3′- ¹⁸ F-Fluorothymidine PET–Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients. Journal of Nuclear Medicine, 2012, 53, 1904-1910.	2.8	44

#	Article	IF	CITATIONS
91	Empowerment in adolescents and young adults with cancer: Relationship with healthâ€related quality of life. Cancer, 2017, 123, 4039-4047.	2.0	44
92	Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016. Cancers, 2020, 12, 3421.	1.7	43
93	Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. Cancer and Metastasis Reviews, 2002, 21, 167-183.	2.7	42
94	Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients. Intensive Care Medicine, 2003, 29, 2157-2161.	3.9	42
95	Emotional and behavioral problems in children of parents recently diagnosed with cancer: A longitudinal study. Acta Oncológica, 2007, 46, 67-76.	0.8	42
96	The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes. ESMO Open, 2020, 5, e000592.	2.0	42
97	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunology, Immunotherapy, 2020, 69, 477-488.	2.0	42
98	Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli Ulcer Functional Limitation Score. Tropical Medicine and International Health, 2003, 8, 90-96.	1.0	41
99	Quality of life of parents with children living at home: when one parent has cancer. Supportive Care in Cancer, 2008, 16, 133-141.	1.0	41
100	Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers. Annals of Surgical Oncology, 2017, 24, 3279-3288.	0.7	41
101	Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Soft Tissue Sarcoma: Three Time Periods at Risk for Amputation. Annals of Surgical Oncology, 2007, 14, 1499-1506.	0.7	40
102	Metastatic potential of an aneurysmal bone cyst. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 455-459.	1.4	40
103	Feasibility and Impact of a Physical Exercise Program in Patients with Advanced Cancer: A Pilot Study. Journal of Palliative Medicine, 2014, 17, 1091-1098.	0.6	40
104	Multidrug resistance proteins in rhabdomyosarcomas. Cancer, 2003, 97, 1999-2005.	2.0	39
105	The Prognostic Effect of the Number of Histologically Examined Axillary Lymph Nodes in Breast Cancer: Stage Migration or Age Association?. Annals of Surgical Oncology, 2006, 13, 465-474.	0.7	39
106	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507. Clinical Cancer Research, 2011, 17, 7693-7703.	3.2	39
107	Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncology, 2013, 9, 1515-1531.	1.1	39
108	Analysis of an IS 2404 -Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. Journal of Clinical Microbiology, 2003, 41, 794-797.	1.8	38

#	Article	IF	CITATIONS
109	Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anti-Cancer Drugs, 2010, 21, 749-758.	0.7	38
110	The HLA class III subregion is responsible for an increased breast cancer risk. Human Molecular Genetics, 2003, 12, 2311-2319.	1.4	37
111	A New Conservative Approach to Extravasation of Anthracyclines with Dimethylsulfoxide and Dexrazoxane. Acta Oncológica, 2001, 40, 541-542.	0.8	37
112	Temsirolimus for metastatic desmoplastic small round cell tumor. Pediatric Blood and Cancer, 2010, 55, 1431-1432.	0.8	36
113	Adolescents' Emotional Reactions to Parental Cancer: Effect on Emotional and Behavioral Problems. Journal of Pediatric Psychology, 2011, 36, 346-359.	1.1	36
114	Epigenetic targeting in pancreatic cancer. Cancer Treatment Reviews, 2014, 40, 656-664.	3.4	36
115	Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients. Annals of Surgical Oncology, 2016, 23, 2745-2752.	0.7	36
116	Online support community for adolescents and young adults (AYAs) with cancer: user statistics, evaluation, and content analysis. Patient Preference and Adherence, 2018, Volume 12, 2615-2622.	0.8	36
117	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. Annals of Surgical Oncology, 2019, 26, 4699-4706.	0.7	36
118	Optimization of IGF-1R SPECT/CT Imaging Using ¹¹¹ In-Labeled F(ab′) ₂ and Fab Fragments of the Monoclonal Antibody R1507. Molecular Pharmaceutics, 2012, 9, 2314-2321.	2.3	35
119	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. American Journal of Medicine, 2013, 126, 174-180.	0.6	35
120	Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: A rational choice. European Journal of Cancer, 2013, 49, 3462-3470.	1.3	35
121	Towards an evidence-based model of fear of cancer recurrence for breast cancer survivors. Journal of Cancer Survivorship, 2017, 11, 41-47.	1.5	35
122	Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?. European Journal of Cancer, 2011, 47, 57-64.	1.3	34
123	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. Clinical Cancer Research, 2015, 21, 3436-3441.	3.2	34
124	Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies. Blood, 2018, 132, 385-392.	0.6	34
125	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist, 2019, 24, 110-116.	1.9	34
126	DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. Clinical Cancer Research, 2020, 26, 93-100.	3.2	34

#	Article	IF	CITATIONS
127	Routine bone scintigraphy in primary staging of soft tissue sarcoma. Cancer, 2000, 89, 1726-1731.	2.0	33
128	Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-? and melphalan. Cancer, 2001, 91, 1940-1948.	2.0	33
129	Age as prognostic factor in patients with osteosarcoma. Bone, 2011, 49, 1173-1177.	1.4	33
130	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1593-602.	3.3	33
131	The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient. International Journal of Clinical Oncology, 2006, 11, 478-481.	1.0	32
132	Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. PLoS ONE, 2015, 10, e0117745.	1.1	32
133	Prevalence and impact of severe fatigue in adolescent and young adult cancer patients in comparison with population-based controls. Supportive Care in Cancer, 2017, 25, 2911-2918.	1.0	32
134	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving firstâ€line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancerâ€Soft Tissue and Bone Sarcoma Group (EORTCâ€STBSG). International Journal of Cancer, 2018, 142, 2610-2620.	2.3	32
135	Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (CIST) treated with adjuvant imatinib (IM): The EORTC/ACITG/FSG/CEIS/ISG randomized controlled phase III trial Journal of Clinical Oncology, 2013, 31, 10500-10500.	0.8	32
136	Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead. Critical Reviews in Oncology/Hematology, 2012, 82, 259-279.	2.0	31
137	Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 266-276.	3.3	31
138	Ageâ€related differences in healthâ€related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry. Head and Neck, 2018, 40, 2235-2245.	0.9	31
139	Stress response symptoms in adolescents during the first year after a parent's cancer diagnosis. Supportive Care in Cancer, 2010, 18, 1421-1428.	1.0	30
140	Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?. World Journal of Surgical Oncology, 2012, 10, 111.	0.8	30
141	A prospective analysis on fatigue and experienced burden in informal caregivers of cancer patients during cancer treatment in the palliative phase. Acta Oncológica, 2015, 54, 500-506.	0.8	30
142	Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 196-201.	0.7	29
143	Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?. Acta Oncológica, 2015, 54, 1202-1208.	0.8	29
144	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Acta Oncol³gica, 2017, 56, 1013-1020.	0.8	29

#	Article	IF	CITATIONS
145	Parentâ€child communication patterns during the first year after a parent's cancer diagnosis. Cancer, 2009, 115, 4227-4237.	2.0	28
146	Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase lb results and prediction of clinical outcome with FDG-PET/CT. Targeted Oncology, 2014, 9, 339-347.	1.7	28
147	Anti-angiogenic therapy, a new player in the field of sarcoma treatment. Critical Reviews in Oncology/Hematology, 2014, 91, 172-185.	2.0	28
148	Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service. Supportive Care in Cancer, 2018, 26, 1479-1487.	1.0	28
149	Age-related sarcoma patient experience: results from a national survey in England. BMC Cancer, 2018, 18, 991.	1.1	28
150	Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care?. Supportive Care in Cancer, 2019, 27, 965-980.	1.0	28
151	A single digital droplet PCR assay to detect multiple <i>KIT</i> exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget, 2018, 9, 13870-13883.	0.8	28
152	Colorectal cancer and theCHEK2 1100delC mutation. Genes Chromosomes and Cancer, 2005, 43, 377-382.	1.5	27
153	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Medical Oncology, 2018, 35, 138.	1.2	26
154	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<scp>DIET</scp> Study). Clinical Pharmacology and Therapeutics, 2019, 106, 1076-1082.	2.3	26
155	Synovial sarcoma diagnosis and management in the era of targeted therapies. Current Opinion in Oncology, 2015, 27, 316-322.	1.1	25
156	Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 848-857.	3.3	25
157	Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib. Targeted Oncology, 2017, 12, 815-826.	1.7	25
158	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. Oncologist, 2018, 23, 1250-1259.	1.9	25
159	Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. Psycho-Oncology, 2014, 23, 773-779.	1.0	24
160	Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors. Journal of Pain and Symptom Management, 2016, 52, 265-271.	0.6	24
161	A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer, 2016, 122, 3501-3508.	2.0	24
162	Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. Journal of Nuclear Medicine, 2018, 59, 194-196.	2.8	24

#	Article	IF	CITATIONS
163	Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A costâ€effectiveness study. British Journal of Clinical Pharmacology, 2019, 85, 1994-2001.	1.1	24
164	Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The "New―Lost Tribe. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 240-246.	2.3	24
165	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. Clinical Cancer Research, 2022, 28, 1402-1411.	3.2	24
166	Radiotherapy plus concomitant and adjuvant temozolomide for leptomeningeal pilomyxoid astrocytoma: a case study. Journal of Neuro-Oncology, 2006, 80, 107-108.	1.4	23
167	Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity $\hat{a} \in$ A retrospective multicentre study in a large cohort of GIST patients. European Journal of Cancer, 2017, 86, 318-325.	1.3	23
168	Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas. Oncologist, 2008, 13, 1193-1200.	1.9	22
169	Clinical applications of positron emission tomography in sarcoma management. Expert Review of Anticancer Therapy, 2011, 11, 195-204.	1.1	22
170	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Research, 2012, 2, 5.	1.1	22
171	Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas. Cancers, 2019, 11, 1780.	1.7	22
172	Unraveling the Heterogeneity of Sarcoma Survivors' Health-Related Quality of Life Regarding Primary Sarcoma Location: Results from the SURVSARC Study. Cancers, 2020, 12, 3083.	1.7	22
173	Decision-making process in patients before entering phase III cancer clinical trials: A pilot study. Cancer Nursing, 1999, 22, 119-125.	0.7	22
174	RELIABILITY AND VALIDITY OF THE BURULI ULCER FUNCTIONAL LIMITATION SCORE QUESTIONNAIRE. American Journal of Tropical Medicine and Hygiene, 2005, 72, 449-452.	0.6	22
175	The Relation Between Histological, Tumor-Biological and Clinical Parameters in Deep and Superficial Leiomyosarcoma and Leiomyoma. Sarcoma, 2002, 6, 105-110.	0.7	21
176	Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. Vaccine Journal, 2004, 11, 387-391.	2.6	21
177	Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. International Journal of Cancer, 2014, 135, 2770-2782.	2.3	20
178	Fatigue and its associated psychosocial factors in cancer patients on active palliative treatment measured over time. Supportive Care in Cancer, 2016, 24, 1349-1355.	1.0	20
179	Caregivers' burden and fatigue during and after patients' treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study. Supportive Care in Cancer, 2019, 27, 4145-4154.	1.0	20
180	Neoadjuvant Systemic Treatment of Primary Angiosarcoma. Cancers, 2020, 12, 2251.	1.7	20

#	Article	IF	CITATIONS
181	Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs) Journal of Clinical Oncology, 2012, 30, 2593-2593.	0.8	20
182	DEVELOPMENT OF A QUESTIONNAIRE ASSESSING BURULI ULCER–INDUCED FUNCTIONAL LIMITATION. American Journal of Tropical Medicine and Hygiene, 2004, 70, 318-322.	0.6	20
183	Non-islet cell tumour hypoglycaemia in a patient with a gastrointestinal stromal tumour. Acta Oncológica, 2005, 44, 764-766.	0.8	19
184	Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. Acta Oncológica, 2006, 45, 175-183.	0.8	19
185	Severe Fatigue During the Palliative Treatment Phase of Cancer. Cancer Nursing, 2014, 37, 139-145.	0.7	19
186	Degree of nephrotoxicity after intermediate―or highâ€dose cisplatinâ€based chemoradiotherapy in patients with locally advanced head and neck cancer. Head and Neck, 2016, 38, E1575-81.	0.9	19
187	Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. Head and Neck, 2016, 38, E559-65.	0.9	19
188	Patient and diagnostic intervals of survivors of sarcoma: Results from the SURVSARC study. Cancer, 2020, 126, 5283-5292.	2.0	19
189	Unravelling the heterogeneity of soft tissue and bone sarcoma patients' health-related quality of life: a systematic literature review with focus on tumour location. ESMO Open, 2020, 5, e000914.	2.0	19
190	Assessing the information desire of patients with advanced cancer by providing information with a decision aid, which is evaluated in a randomized trial: a study protocol. BMC Medical Informatics and Decision Making, 2011, 11, 9.	1.5	18
191	The relationship between sunitinib exposure and both efficacy and toxicity in realâ€world patients with renal cell carcinoma and gastrointestinal stromal tumour. British Journal of Clinical Pharmacology, 2021, 87, 326-335.	1.1	18
192	New Systemic Therapy Options for Advanced Sarcomas. Current Treatment Options in Oncology, 2012, 13, 306-317.	1.3	17
193	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncolmmunology, 2016, 5, e1191732.	2.1	17
194	Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences. Journal of Cancer Education, 2016, 31, 443-448.	0.6	17
195	Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. Quality of Life Research, 2018, 27, 3097-3111.	1.5	17
196	The patient perspective in the era of personalized medicine: What about scanxiety?. Cancer Medicine, 2021, 10, 2943-2945.	1.3	17
197	No association between two MLH3 variants (S845G and P844L)and colorectal cancer risk. Cancer Genetics and Cytogenetics, 2004, 152, 70-71.	1.0	15
198	Imaging of HIV-Associated Kaposi Sarcoma; F-18-FDG-PET/CT and In-111-Bevacizumabscintigraphy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 444-446.	0.9	15

#	Article	IF	CITATIONS
199	Nuclear Medicine Imaging of Infection in Cancer Patients (With Emphasis on FDG-PET). Oncologist, 2011, 16, 980-991.	1.9	15
200	Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). Cancer Chemotherapy and Pharmacology, 2014, 74, 457-463.	1.1	15
201	Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry. Cancers, 2020, 12, 730.	1.7	15
202	Diagnosed with a Rare Cancer: Experiences of Adult Sarcoma Survivors with the Healthcare System—Results from the SURVSARC Study. Cancers, 2021, 13, 679.	1.7	15
203	Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. Cancers, 2022, 14, 1832.	1.7	15
204	Syndrome X in testicularcancer survivors. Lancet, The, 2001, 357, 228-229.	6.3	14
205	â€~Big'-Insulin-Like Growth Factor–II Signaling Is an Autocrine Survival Pathway in Gastrointestinal Stromal Tumors. American Journal of Pathology, 2012, 181, 303-312.	1.9	14
206	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. Sarcoma, 2018, 2018, 1-8.	0.7	14
207	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Medical Oncology, 2018, 35, 131.	1.2	14
208	No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors. European Journal of Cancer, 2005, 41, 1819-1823.	1.3	13
209	Temperament as a predictor of internalising and externalising problems in adolescent children of parents diagnosed with cancer. Supportive Care in Cancer, 2007, 15, 395-403.	1.0	13
210	Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. Acta Oncológica, 2010, 49, 113-116.	0.8	13
211	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. Anticancer Research, 2019, 39, 4891-4896.	0.5	13
212	Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1659-1670.	1.2	13
213	Health-Related Quality of Life Issues in Adolescents and Young Adults with Cancer: Discrepancies with the Perceptions of Health Care Professionals. Journal of Clinical Medicine, 2021, 10, 1833.	1.0	13
214	BURULI ULCER AND SCHISTOSOMIASIS: NO ASSOCIATION FOUND. American Journal of Tropical Medicine and Hygiene, 2004, 71, 318-321.	0.6	13
215	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. Journal of Nuclear Medicine, 2012, 53, 1926-1932.	2.8	12
216	Experiences of Parents and General Practitioners with End-of-Life Care in Adolescents and Young Adults with Cancer. Journal of Adolescent and Young Adult Oncology, 2016, 5, 64-68.	0.7	12

#	Article	IF	CITATIONS
217	Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial. BMC Medical Informatics and Decision Making, 2017, 17, 130.	1.5	12
218	Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE) Tj ETQq0 C) 0 rg BT /C	verbock 10 Tf
219	Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study. European Journal of Cancer, 2019, 113, 32-40.	1.3	12
220	Methotrexate plus or minus cetuximab as firstâ€line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ibâ€randomized phase II study Commence. Head and Neck, 2020, 42, 828-838.	0.9	12
221	Testicular carcinoma and HLA Class II genes. Cancer, 2002, 95, 1857-1863.	2.0	11
222	Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. Clinical Biochemistry, 2008, 41, 636-639.	0.8	11
223	Olaratumab in soft-tissue sarcomas. Lancet, The, 2016, 388, 442-444.	6.3	11
224	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. Acta Oncológica, 2018, 57, 1117-1126.	0.8	11
225	EORTC SPECTAâ€AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. International Journal of Cancer, 2020, 147, 1180-1184.	2.3	11
226	Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT). Trials, 2020, 21, 86.	0.7	11
227	Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanismsIn Vitro. International Journal of Cancer, 1993, 55, 330-337.	2.3	10
228	The dilemma of the strive for apoptosis in oncology: mind the heart. Critical Reviews in Oncology/Hematology, 2005, 53, 101-113.	2.0	10
229	The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab′)2-R1507 fragments in Ewing sarcomas. European Journal of Cancer, 2013, 49, 2851-2858.	1.3	10
230	Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects. Head and Neck, 2013, 35, E246-50.	0.9	10
231	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Physics, 2015, 2, 5.	1.3	10
232	The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial. BMC Cancer, 2016, 16, 520.	1.1	10
233	Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. Acta Oncolųgica, 2016, 55, 1510-1512.	0.8	10
234	The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. European Journal of Cancer, 2017, 84, 257-261.	1.3	10

#	Article	IF	CITATIONS
235	Does a regular nurseâ€led distress screening and discussion improve quality of life of breast cancer patients treated with curative intent? A randomized controlled trial. Psycho-Oncology, 2020, 29, 719-728.	1.0	10
236	Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. Journal of Adolescent and Young Adult Oncology, 2020, 9, 628-638.	0.7	10
237	â€~This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39Âyears at diagnosis. European Journal of Cancer Care, 2021, 30, e13458.	0.7	10
238	The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options. Seminars in Oncology, 2021, 48, 111-118.	0.8	10
239	Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?. Biomedicines, 2021, 9, 1315.	1.4	10
240	Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients. Cancers, 2022, 14, 436.	1.7	10
241	Health-Related Quality of Life in Patients With Sarcoma: Enhancing Personalized Medicine. Journal of Clinical Oncology, 2018, 36, 1642-1643.	0.8	9
242	Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy. Acta Oncológica, 2020, 59, 975-982.	0.8	9
243	The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study. Cancers, 2021, 13, 3068.	1.7	9
244	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. Molecular Pharmaceutics, 2014, 11, 4249-4257.	2.3	8
245	Promising management of pazopanib-induced liver toxicity. Acta Oncológica, 2015, 54, 1064-1066.	0.8	8
246	Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. Clinical Sarcoma Research, 2017, 7, 2.	2.3	8
247	Fatal heart failure in a young adult female sarcoma patient treated with pazopanib. Acta Oncológica, 2017, 56, 1233-1234.	0.8	8
248	Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. Future Oncology, 2017, 13, 185-194.	1.1	8
249	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. Anticancer Research, 2019, 39, 1309-1316.	0.5	8
250	Health-related quality Of Life I n patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. BMJ Open, 2020, 10, e035171.	0.8	8
251	The complexity of assessing health-related quality of life among sarcoma patients. Quality of Life Research, 2020, 29, 2613-2614.	1.5	8
252	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. European Journal of Cancer, 2021, 154, 253-268.	1.3	8

#	Article	IF	CITATIONS
253	The impact of a 1â€hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. International Journal of Cancer, 2021, 148, 2799-2806.	2.3	8
254	Salivary duct carcinoma: Clinical outcomes and prognostic factors in 157 patients and results of androgen deprivation therapy in recurrent disease (n=31)—Study of the Dutch head and neck society (DHNS) Journal of Clinical Oncology, 2016, 34, 6016-6016.	0.8	8
255	The route to diagnosis of sarcoma patients: Results from an interview study in the Netherlands and the United Kingdom. PLoS ONE, 2020, 15, e0243439.	1.1	8
256	Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis. Cancers, 2022, 14, 709.	1.7	8
257	Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. Journal of Cancer Research and Clinical Oncology, 2004, 130, 581-590.	1.2	7
258	The Human Leukocyte Antigen Region and Colorectal Cancer Risk. Diseases of the Colon and Rectum, 2005, 48, 303-306.	0.7	7
259	Molecular imaging of solid tumors: exploiting the potential. Nature Reviews Clinical Oncology, 2009, 6, 609-611.	12.5	7
260	18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors. World Journal of Nuclear Medicine, 2012, 11, 65-69.	0.3	7
261	IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. Future Oncology, 2013, 9, 1733-1740.	1.1	7
262	Radionuclide imaging of drug delivery for patient selection in targeted therapy. Expert Opinion on Drug Delivery, 2014, 11, 175-185.	2.4	7
263	Expected survival with and without secondâ€line palliative chemotherapy: who wants to know?. Health Expectations, 2015, 18, 2903-2914.	1.1	7
264	Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?. British Journal of Clinical Pharmacology, 2017, 83, 2312-2314.	1.1	7
265	The Perceived Impact of Length of the Diagnostic Pathway Is Associated with Health-Related Quality of Life of Sarcoma Survivors: Results from the Dutch Nationwide SURVSARC Study. Cancers, 2020, 12, 2088.	1.7	7
266	Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries. Sarcoma, 2020, 2020, 1-9.	0.7	7
267	PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study. BMJ Open, 2020, 10, e039449.	0.8	7
268	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. European Journal of Surgical Oncology, 2022, 48, 500-507.	0.5	7
269	Next Step for Global Adolescent and Young Adult Oncology: A Core Patient-Centered Outcome Set. Journal of the National Cancer Institute, 2022, 114, 496-502.	3.0	7
270	5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer, 1995, 75, 1072-1076.	2.0	6

#	Article	IF	CITATIONS
271	FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment. Nuclear Medicine and Molecular Imaging, 2015, 49, 237-240.	0.6	6
272	Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?. Acta Oncológica, 2016, 55, 444-448.	0.8	6
273	Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or highâ€dose cisplatinâ€based chemoradiotherapy. Head and Neck, 2019, 41, 488-494.	0.9	6
274	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. European Journal of Cancer, 2018, 101, 55-61.	1.3	6
275	Genomic and transcriptomic characterization of desmoplastic small round cell tumors. Genes Chromosomes and Cancer, 2021, 60, 595-603.	1.5	6
276	Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here?. Lancet Oncology, The, 2017, 18, 706-707.	5.1	6
277	Teniposide for meningeal carcinomatosis of small cell lung cancer. Lung Cancer, 1993, 10, 247-249.	0.9	5
278	Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron. Cancer Chemotherapy and Pharmacology, 1995, 36, 477-482.	1.1	5
279	Effects of peripheral stem-cell or bone-marrow reinfusion on peripheral serotonin metabolism. Lancet, The, 1999, 353, 293-294.	6.3	5
280	When Hope Is All There Is Left. Oncologist, 2011, 16, 914-916.	1.9	5
281	Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway. Anti-Cancer Drugs, 2012, 23, 149-154.	0.7	5
282	Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle. Targeted Oncology, 2015, 10, 439-443.	1.7	5
283	Redefining the standard of care in metastatic leiomyosarcoma. Lancet Oncology, The, 2015, 16, 360-362.	5.1	5
284	The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma. British Journal of Clinical Pharmacology, 2016, 81, 768-772.	1.1	5
285	Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. Supportive Care in Cancer, 2018, 26, 1233-1242.	1.0	5
286	The effect of gastrectomy on regorafenib exposure and progressionâ€free survival in patients with advanced gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2019, 85, 2399-2404.	1.1	5
287	Comprehensive Assessment of Incidence, Risk Factors, and Mechanisms of Impaired Medical and Psychosocial Health Outcomes among Adolescents and Young Adults with Cancer: Protocol of the Prospective Observational COMPRAYA Cohort Study. Cancers, 2021, 13, 2348.	1.7	5
288	Differences in Internet Use and eHealth Needs of Adolescent and Young Adult Versus Older Cancer Patients; Results from the PROFILES Registry. Cancers, 2021, 13, 6308.	1.7	5

#	Article	IF	CITATIONS
289	Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes. Cancers, 2022, 14, 2979.	1.7	5
290	Pazopanib for metastatic soft-tissue sarcoma – Authors' reply. Lancet, The, 2012, 380, 801.	6.3	4
291	Dynamics of IGF-1R Expression During Endocrine Breast Cancer Treatment. Molecular Imaging and Biology, 2014, 16, 529-37.	1.3	4
292	How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death. Palliative and Supportive Care, 2016, 14, 241-249.	0.6	4
293	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients Journal of Clinical Oncology, 2012, 30, 10009-10009.	0.8	4
294	Dying at the Right Time: A Modern Dilemma. Oncologist, 2009, 14, 642-643.	1.9	3
295	Exploring the Routine Administration of Decision Aids for Palliative Chemotherapy to Patients by Nurses. Cancer Nursing, 2015, 38, 270-278.	0.7	3
296	Describing Unmet Supportive Care Needs among Young Adults with Cancer (25–39 Years) and the Relationship with Health-Related Quality of Life, Psychological Distress, and Illness Cognitions. Journal of Clinical Medicine, 2021, 10, 4449.	1.0	3
297	Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review. BMJ Open, 2021, 11, e042404.	0.8	3
298	Induction chemotherapy (IC) with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing concomitant chemoradiotherapy (CRT) in fit patients with locally advanced head and neck cancer (LAHNC): The CONDOR study—A study of the Dutch Head and Neck Society Journal of Clinical Oncology, 2013, 31, 6057-6057.	0.8	3
299	Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2293-2307.	0.9	3
300	Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data. Supportive Care in Cancer, 2022, 30, 5137-5146.	1.0	3
301	Firstâ€line chemotherapy in advanced intraâ€abdominal wellâ€differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Cancer, 2022, 128, 2932-2938.	2.0	3
302	In vitro and in vivo studies on the action of BW502U83, an arylmethylaminopropanediol. Anti-Cancer Drugs, 1995, 6, 34-39.	0.7	2
303	Time to practice what we preach? Appreciating the autonomy of cancer patients on deciding whether they want to be informed about interventional studies for fatigue. Palliative Medicine, 2016, 30, 897-898.	1.3	2
304	Q uality of life and experiences of sarcoma trajectories (the QUEST study): protocol for an international observational cohort study on diagnostic pathways of sarcoma patients. BMJ Open, 2020, 10, e039309.	0.8	2
305	PARP inhibition in UV-associated angiosarcoma preclinical models. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2579-2590.	1.2	2
306	Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. , 2001, 91, 1304.		2

#	Article	IF	CITATIONS
307	Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS) Journal of Clinical Oncology, 2014, 32, 10579-10579.	0.8	2
308	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. Journal of Clinical Oncology, 2019, 37, 4564-4564.	0.8	2
309	Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer Journal of Clinical Oncology, 2020, 38, 3613-3613.	0.8	2
310	The Prolonged Diagnostic Pathway of Young Adults (Aged 25–39) with Cancer in the United Kingdom: Results from the Young Adult Cancer Patient Journey Study. Journal of Clinical Medicine, 2021, 10, 4646.	1.0	2
311	Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group. Journal of Clinical Medicine, 2021, 10, 5334.	1.0	2
312	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Research, 2015, 35, 5601-6.	0.5	2
313	â€ĩI thought I had fibroids, and now I don't': a mixed method study on health-related quality of life in uterine sarcoma patients. Health and Quality of Life Outcomes, 2022, 20, 65.	1.0	2
314	The African challenge. Lancet, The, 2002, 359, 1527-1528.	6.3	1
315	Time to target evaluation criteria of targeted therapies. Nuclear Medicine Communications, 2009, 30, 487-489.	0.5	1
316	FELD better not thinking of metastases only when liver lesions appear after bleomycin-based treatment for non-seminoma testis from metastases. BMC Cancer, 2013, 13, 491.	1.1	1
317	Young adults: a unique group in cancer epidemiological research. Lancet Oncology, The, 2018, 19, e72.	5.1	1
318	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. Sarcoma, 2019, 2019, 1-11.	0.7	1
319	Clinical Trials for Real-World Elderly Patients With Metastatic Soft-Tissue Sarcomas: The Importance of Study Design and Patient-Reported Outcomes. Journal of Clinical Oncology, 2021, 39, 860-861.	0.8	1
320	Supportive care needs of patients living with an extremely rare and unpredictable cancer: The Epithelioid Haemangioendothelioma patient experience. European Journal of Cancer Care, 2021, 30, e13461.	0.7	1
321	A phase Ib study of the combination of temsirolimus (T) and pegylated liposomal doxorubicin (PLD) in advanced or recurrent breast, endometrial, and ovarian cancer Journal of Clinical Oncology, 2012, 30, 5061-5061.	0.8	1
322	Association of genetic variants involved in drug metabolism and transport with efficacy and toxicity of chemotherapeutic treatment in osteosarcoma patients Journal of Clinical Oncology, 2014, 32, 10038-10038.	0.8	1
323	Clinical characteristics and treatment outcome in a large multicenter observational cohort of pdgfra exon 18 mutated gastrointestinal stromal tumor (GIST) patients Journal of Clinical Oncology, 2016, 34, 11011-11011.	0.8	1
324	Prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC) Journal of Clinical Oncology, 2016, 34, 6079-6079.	0.8	1

#	Article	IF	CITATIONS
325	Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials Journal of Clinical Oncology, 2017, 35, 10536-10536.	0.8	1
326	Incidence and survival trends of cancers diagnosed in young adults (20-39 years): A population-based study Journal of Clinical Oncology, 2017, 35, 1567-1567.	0.8	1
327	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE Journal of Clinical Oncology, 2018, 36, 11540-11540.	0.8	1
328	TIRED: A randomised controlled trial evaluating efficacy of cognitive behavior therapy and graded exercise therapy in severely fatigue patients with advanced cancer Journal of Clinical Oncology, 2018, 36, 183-183.	0.8	1
329	Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. Nuklearmedizin - NuclearMedicine, 2021, 60, 411-416.	0.3	1
330	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSC) Database. Sarcoma, 2022, 2022, 1-13.	0.7	1
331	A Sarcoid-like Reaction in a Patient with Hemangiopericytoma Mediastinal lymphadenopathy resulting in Confusion about Therapy. Acta Oncológica, 2003, 42, 790-791.	0.8	0
332	Malignant Transformation in an Area With Elevated F-18 FDG Uptake Within a Low Metabolic Benign Neurofibroma. Clinical Nuclear Medicine, 2010, 35, 271-272.	0.7	0
333	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Research, 2019, 39, 347-351.	0.5	0
334	Bone sarcoma during pregnancy: an example of personalized multidisciplinary care. Acta Oncológica, 2019, 58, 128-131.	0.8	0
335	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. Journal of Clinical Oncology, 2021, 39, e23539-e23539.	0.8	0
336	Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo Journal of Clinical Oncology, 2012, 30, 10067-10067.	0.8	0
337	Patient information desire in actual decision making for advanced cancer treatment: Do doctors know their patients?. Journal of Clinical Oncology, 2012, 30, 9036-9036.	0.8	0
338	The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies Journal of Clinical Oncology, 2012, 30, 3035-3035.	0.8	0
339	Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS): Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072 Journal of Clinical Oncology, 2013, 31, 10553-10553.	0.8	0
340	A randomized trial of a nurse-led decision aid to inform patients with advanced cancer about palliative chemotherapy Journal of Clinical Oncology, 2013, 31, e20583-e20583.	0.8	0
341	Fear of disease progression in patients with gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2013, 31, 10549-10549.	0.8	0
342	Degree of nephrotoxicity after intermediate or high-dose cisplatin-based chemoradiotherapy (CRT) in patients with locally advanced head and neck cancer (LAHNC) Journal of Clinical Oncology, 2014, 32, 6056-6056.	0.8	0

#	Article	IF	CITATIONS
343	Quality of life of patients with locally advanced head and neck cancer (LAHNC) treated with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing chemoradiotherapy (CRT) Journal of Clinical Oncology, 2014, 32, 6053-6053.	0.8	0
344	Survival of adolescents and young adults (AYAs) with skeletal Ewing sarcoma: A Dutch population-based study Journal of Clinical Oncology, 2014, 32, 10530-10530.	0.8	0
345	Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in the Netherlands Journal of Clinical Oncology, 2014, 32, 10542-10542.	0.8	0
346	Pharmacogenetic markers for efficacy and toxicity of chemotherapy in osteosarcoma patients Journal of Clinical Oncology, 2015, 33, 10054-10054.	0.8	0
347	A biopsy-guided analysis of diarrhea in patients treated with tyrosine kinase inhibitors of the vascular endothelial growth factor receptor Journal of Clinical Oncology, 2015, 33, e15596-e15596.	0.8	0
348	Association of pharmacogenetic variants with progressive disease in osteosarcoma patients Journal of Clinical Oncology, 2015, 33, 10057-10057.	0.8	0
349	Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database Journal of Clinical Oncology, 2015, 33, 10544-10544.	0.8	0
350	Prognostic factors for overall survival of patients with head and neck soft tissue sarcoma based on 25 years data from the Netherlands Cancer registry Journal of Clinical Oncology, 2016, 34, 6050-6050.	0.8	0
351	Genetic variants as predictive markers for ototoxicity and nephrotoxicity in patients (pts) with locally advanced head and neck cancer (LAHNC) treated with cisplatin-containing chemoradiotherapy (ccCRT) Journal of Clinical Oncology, 2018, 36, e18010-e18010.	0.8	0
352	The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure Journal of Clinical Oncology, 2019, 37, e22511-e22511.	0.8	0
353	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202 Journal of Clinical Oncology, 2020, 38, 11556-11556.	0.8	0
354	Psychosocial consequences of surviving cancer diagnosed and treated in childhood versus in adolescence/young adulthood: A call for clearer delineation between groups. Cancer, 2022, 128, 2690-2694.	2.0	0
355	Clinical trials in Desmoidâ€type Fibromatosis in children and (young) adults: A systematic review. Pediatric Blood and Cancer, 0, , .	0.8	Ο